Mediar Therapeutics is planning to launch a Phase 2 clinical trial in the first half of 2025 to test its IPF therapy MTX-463.
Mediar Therapeutics has entered a global licensing agreement with Eli Lilly and Company to progress the human immunoglobulin ...
Hosted on MSN19d
Lilly signs licensing deal with Mediar for IPF drugMediar said it expects to initiate a Phase 2 study in the first half of 2025. After the study is completed, Lilly (NYSE:LLY) will have the right to lead further development and commercialization ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback